Osteoarticular diseases are the main cause of disability in developed countries, having a significant impact on people’s quality of life and their ability to work (reduction of working days, lower incomes, etc.). The economic impact of these diseases is now estimated at almost EUR 100 billion per year for all the countries of the European Union. With this in mind, the CHU Montpellier, in association with the University of Montpellier, wishes to develop a new research platform combining state-of-the-art imaging and tissue engineering technologies. The Cartigen platform should allow for the development of research: •In the field of movement and mobility, based on motion capture imaging, in order to offer personalised rehabilitation of patients; •In the field of bioprostheses, based on the latest advances in the field of stem cells and 3D printing, in order to offer personalised regenerative medicine. The Cartigen platform will be set up and structured in collaboration with Trinoma (specialised in mobility), Bauerfeind (specialised in prosthetics), 3D MEDLAB (specialised in 3D printing) and MedXcell (specialised in stem cells).